UBS Group AG Has $596.59 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX

Key Points

• UBS Group AG trimmed its Abivax position by 0.8% in Q4, leaving it with 4,423,906 shares—about a 5.64% stake valued at $596.59 million according to its latest 13F filing.
• Analyst coverage is broadly positive with a MarketBeat consensus of "Moderate Buy" and an average price target of $137.15 (one Strong Buy, 13 Buy, one Sell).
• Abivax is a clinical-stage biotech (lead drug obefazimod) with a market cap of $9.08 billion, recent quarterly EPS of -$1.20 and an expected FY EPS of -3.84, and a 12‑month trading range of $5.59–$148.83.

UBS Group AG lessened its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,423,906 shares of the company's stock after selling 37,356 shares during the quarter. UBS Group AG owned 5.64% of Abivax worth $596,586,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after purchasing an additional 369 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Abivax in the 3rd quarter valued at $36,000. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in shares of Abivax in the 3rd quarter valued at $52,000. Finally, WPG Advisers LLC boosted its holdings in shares of Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Wall Street Analysts Forecast Growth

ABVX has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Abivax in a report on Monday, April 20th. BTIG Research reissued a "buy" rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Wedbush assumed coverage on Abivax in a report on Tuesday, February 24th. They set an "outperform" rating and a $110.00 price objective on the stock. Oppenheimer set a $131.00 price objective on Abivax in a report on Thursday, January 8th. Finally, Oddo Bhf reissued an "outperform" rating on shares of Abivax in a report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $137.15.

Abivax Price Performance

NASDAQ ABVX opened at $114.56 on Monday. Abivax SA Sponsored ADR has a twelve month low of $5.59 and a twelve month high of $148.83. The company has a market cap of $9.08 billion, a price-to-earnings ratio of -21.33 and a beta of 1.68. The business's fifty day moving average is $118.27 and its 200 day moving average is $116.10.

Abivax (NASDAQ:ABVX - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The company had revenue of $0.52 million during the quarter. On average, research analysts anticipate that Abivax SA Sponsored ADR will post -3.84 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.